The biopharma industry is abuzz with the recent announcement that Cristian Massacesi, former chief medical officer at AstraZeneca, will be stepping into the role of chief medical officer at Bristol Myers Squibb. Massacesi’s wealth of experience in shaping AstraZeneca’s pipeline, particularly in the oncology sector, is expected to bring valuable insights and advancements to Bristol Myers Squibb. During his tenure at AstraZeneca, Massacesi focused on building a robust oncology drug portfolio, with investments in areas such as radiopharma, antibody-drug conjugates, and cell therapy.
His appointment comes as Bristol Myers Squibb looks to continue its trajectory of success in bringing innovative drugs to market, with recent launches like Sotyktu, Reblozyl, Camzyos, Opdualag, and Cobenfy. Reblozyl, in particular, has already achieved blockbuster status, generating significant revenue for the company. Under the leadership of outgoing executive Samit Hirawat, Bristol Myers Squibb made strategic moves to enhance its pipeline, including acquisitions in the cancer drug space and partnerships with key players like BioNTech. With Massacesi at the helm, the company is poised to further its mission of driving impactful medical innovation and staying at the forefront of the biopharma industry.
Read more from biopharmadive.com